# ‚öîÔ∏è TRIAL INTELLIGENCE REPORT: NCT05445778 ‚öîÔ∏è

**Trial Name**: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizuma...  
**Patient**: Ayesha Kiani (ID: ayesha_001)  
**Generated**: 2025-11-15T21:55:51.039675  
**Generated By**: Zo (Lead Commander)  
**Match Tier**: TOP_TIER  
**Composite Score**: 0.97/1.00  
**Eligibility Probability**: ~100%

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT05445778

---

## üî• WHY THIS MATTERS FOR AYESHA - CRITICAL ANALYSIS

**Status**: RECRUITING  
**Phase**: N/A  
**Sponsor**: Not specified

### ‚úÖ PIPELINE ASSESSMENT:

‚úÖ Status: RECRUITING
‚úÖ Ovarian cancer trial match
‚úÖ No stage restriction (assume eligible)
- ‚úÖ INTERVENTIONAL treatment trial
- ‚úÖ 4 NYC metro location(s)
- ‚ö†Ô∏è Eligibility: ~100% (pending biomarkers)

**Semantic Similarity**: 0.000 (vector search match)

---

## üß¨ ELIGIBILITY ASSESSMENT FOR AYESHA

| Criterion | Ayesha's Status | Match | Action Required |
|-----------|-----------------|-------|-----------------|
| Stage IV epithelial ovarian | Stage IVB High-Grade Serous Ovarian Carcinoma (HGSOC) | ‚úÖ PASS | None |
| BRCA wildtype | Germline negative | ‚úÖ PASS | None |
| HER2 Status | UNKNOWN | ‚ö†Ô∏è GATE | HER2 IHC (3-5 days) |
| HRD Status | UNKNOWN | ‚ö†Ô∏è PENDING | MyChoice CDx (7-10 days) |
| Treatment Line | first-line | ‚úÖ PASS | None |
| Tissue Available | True | ‚úÖ PASS | None |
| Performance Status | ECOG 1 | ‚úÖ PASS | None |
| Geographic Access | NYC Metro | ‚úÖ PASS | None |

**Probability Ayesha Is Eligible**: ~100%  
**Calculation**: No specific restrictions (100% eligible)

---

## üéØ WHY THIS TRIAL IS A GOOD FIT FOR AYESHA (LLM Analysis)

### **Clinical Trial Analysis for Ayesha Kiani (40F, HGSOC Stage IVB)**

**Patient:** Ayesha Kiani
**Trial:** NCT05445778 (GLORIOSA)

**Executive Summary:**
Ayesha Kiani is **not currently eligible** for the GLORIOSA (NCT05445778) trial. The fundamental reason for ineligibility is the trial's requirement for patients with **platinum-sensitive relapsed disease**, whereas Ms. Kiani is treatment-naive and about to begin first-line therapy. While the trial's intervention is conceptually promising for her disease biology, it is designed as a maintenance strategy in a later-line setting. The following analysis details the rationale behind this conclusion and outlines future considerations.

---

#### **1. Drug Mechanism Fit**

The combination of mirvetuximab soravtansine and bevacizumab is highly relevant to Ms. Kiani's HGSOC biology, but at a future time point.

*   **Mirvetuximab Soravtansine (Mirv):** This is an antibody-drug conjugate (ADC) targeting Folate Receptor-alpha (FRŒ±). Up to 80% of HGSOC tumors, particularly those that are BRCA wildtype, exhibit high FRŒ± expression. Mirvetuximab delivers a potent microtubule-disrupting agent (DM4) directly to cancer cells, maximizing efficacy while potentially minimizing systemic toxicity. For a patient with a high tumor burden, including extensive pleural metastases, this targeted cell-kill mechanism is an excellent theoretical fit. However, her FRŒ± status is currently unknown and would require testing.
*   **Bevacizumab (Bev):** As an anti-VEGF agent, bevacizumab is already part of her planned standard of care (SOC). It is particularly effective in HGSOC for controlling ascites and pleural effusions by decreasing vascular permeability. Its anti-angiogenic mechanism would complement the cytotoxic action of mirvetuximab.

Given Ms. Kiani's BRCA-negative status (HRD unknown), non-PARP inhibitor targeted therapies like mirvetuximab are of high interest. The drug mechanism is a strong potential match for her tumor biology, but the trial's timing is incorrect.

#### **2. Location Logistics**

The trial's logistical profile is highly favorable. The available NYC sites are:
*   **Icahn School of Medicine at Mount Sinai** (New York, NY)
*   **NYU Laura and Isaac Perlmutter Cancer Center** (New York, NY)

Living in East Harlem (ZIP 10029), Ms. Kiani has excellent access to these centers. The Icahn School of Medicine is located at the Mount Sinai Hospital campus, which is within walking or very short travel distance from her home. NYU Langone is also easily accessible via a short subway or taxi ride (approx. 20-30 minutes). The convenience of these top-tier cancer centers would significantly reduce the travel burden often associated with clinical trial participation.

#### **3. Risk-Benefit for Ayesha**

Analyzing this hypothetically for a future time point:

*   **Potential Benefits:** If she were to become platinum-sensitive relapsed, the primary benefit would be a potentially more effective maintenance strategy than bevacizumab alone, which is a standard option for BRCA-negative/HRD-negative patients. The goal would be to extend her progression-free survival (PFS).
*   **Potential Risks & Safety Concerns:**
    *   **Pulmonary Status:** Ms. Kiani's compromised pulmonary function from large pleural effusions is a major consideration. Bevacizumab is beneficial for controlling effusions. Mirvetuximab's primary toxicities do not directly target the lungs; however, any treatment-related complication (e.g., neutropenic fever) would pose a heightened risk in a patient with limited pulmonary reserve.
    *   **Toxicity Profile:** The key adverse events of mirvetuximab include ocular toxicity (keratopathy, blurred vision), neuropathy, and myelosuppression. The ocular toxicity is common and requires diligent monitoring with eye exams. Any pre-existing or paclitaxel-induced neuropathy from her first-line therapy would be a risk factor for worsening symptoms. Given her good performance status (ECOG 1), she would likely be a candidate to tolerate this regimen, but a thorough assessment post-induction therapy would be essential.

#### **4. Comparison to Standard of Care**

This trial is **not an alternative to her planned SOC; it is a potential *sequel* to it.**

*   **Current SOC (Induction):** Carboplatin + Paclitaxel + Bevacizumab is the appropriate, evidence-based first-line treatment for a patient with Stage IVB HGSOC. It is critical she proceeds with this induction therapy to debulk her extensive tumor burden and control her symptoms, particularly the pleural effusions.
*   **Trial (Maintenance):** The GLORIOSA trial evaluates maintenance therapy *after* a patient has completed first-line platinum-based chemotherapy, achieved a response, and then subsequently relapsed but remains platinum-sensitive. The trial compares Mirv+Bev maintenance to Bev-alone maintenance. For a BRCA-negative patient, Bev-alone is a standard maintenance option. The trial asks if adding Mirv is superior.

Therefore, she should absolutely **stick with her planned SOC**. The trial is not a competing option at this time.

#### **5. Critical Considerations for the Care Team**

1.  **Confirm Ineligibility:** The primary action is to confirm with her care team that she is ineligible for GLORIOSA due to her treatment-naive status. This avoids confusion and false hope.
2.  **Immediate Action - Biomarker Testing:** The care team should immediately send her tumor tissue for comprehensive biomarker testing, including **FRŒ± expression (via the Ventana FOLR1 assay) and HRD status**. This information is not urgent for her first-line treatment but will be absolutely critical for planning all future lines of therapy and identifying eligibility for future trials or approved targeted agents.
3.  **Future Planning:** While she is undergoing first-line therapy, this trial should be "bookmarked" as a highly relevant potential option for the future. If she responds well to her initial chemotherapy but relapses more than 6 months after completion (defining her as platinum-sensitive), and her tumor is confirmed to have high FRŒ± expression, she would then become an ideal candidate for this study.
4.  **Focus on Current Treatment:** The immediate priority is the safe and effective administration of her first-line chemotherapy to manage her high tumor burden and resolve her life-limiting pleural effusions. Trial considerations should not delay the initiation of this critical therapy.

---


## üö® CRITICAL DECISION TREE FOR AYESHA

START: Ayesha completes carboplatin + paclitaxel + bevacizumab (L1)
  ‚îÇ
  ‚îú‚îÄ‚Üí Biomarker Testing (if required)
  ‚îÇ    ‚îÇ
  ‚îÇ    ‚îî‚îÄ‚Üí **ELIGIBLE FOR TRIAL!** (pending results)
  ‚îÇ         Probability: ~100%
  ‚îÇ
  ‚îî‚îÄ‚Üí END: Enroll in NCT05445778

---

## üí° STRATEGIC IMPLICATIONS

### Best-Case Scenario:
‚úÖ Ayesha enrolls in NCT05445778
‚úÖ Access to experimental therapy
‚úÖ Close monitoring, expert care
**Probability**: ~100%

### Most Likely Scenario:
Ayesha completes screening and enrolls successfully (pending biomarkers)

### Challenge Scenario:
Screen failure due to biomarker requirements or other eligibility criteria

---

## üìã FULL ELIGIBILITY TEXT

### Eligibility Criteria
1. Adult women \>/=18 years old
2. Confirmed diagnosis of high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer
3. Confirmed high FRŒ± expression by regulatory-agency approved Ventana FOLR1 (FOLR1-2.1)
4. Relapsed disease after frontline (first-line) platinum-based chemotherapy and must be plantinum-sensitive
5. Willing and able to sign the informed consent form (ICF) and adhere to protocol requirements
6. Negative pregnancy test and willing to use highly effective contraceptive method(s) while on study medication and for at least 7 months after the last dose of MIRV and 6 months after the last dose of bevacizumab 1. Endometrioid, clear cell, mucinous, or sarconmatous histology; mixed tumors containing any of the above or low grade/borderline ovarian tumor
2. More than one line of prior chemotherapy before current/planned triplet therapy
3. PD (progressive disease) while on or following platinum-based therapy
4. Prior or whole-pelvis or wide-field radiotherapy
5. \> Grade 1 peripheral neuropathy
6. History of or concurrent ocular disorders
7. Grade 4 thromboembolic events
8. Not appropriate for bevacizumab treatment
9. Requiring use of folate-containing supplements
10. Prior hypersensitivity to monoclonal antibodies
11. Pregnant or breatfeeding women
12. Received prior MIRV or other FRŒ±-targeting agents
13. Untreated or symptomatic central nervous system metastases
14. History of other malignancy within 3 years prior to signing study consent

---

## üìä TRIAL DESCRIPTION

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRŒ±) expression.

---

## üè• LOCATION DETAILS

### NYC Metro Locations (Priority for Ayesha)

1. **Mount Sinai Medical Center /ID# 269582** - Miami, Florida
2. **John Theurer Cancer Center /ID# 269109** - Hackensack, New Jersey
3. **NYU Laura and Isaac Perlmutter Cancer Center /ID# 269556** - New York, New York
4. **Icahn School of Medicine at Mount Sinai /ID# 269529** - New York, New York

---

## ‚ö†Ô∏è CRITICAL GATES FOR AYESHA

‚úÖ No critical biomarker gates identified. Proceed with standard eligibility screening.

---

## ‚öîÔ∏è TACTICAL RECOMMENDATIONS

**Priority**: üî• **P0 - IMMEDIATE ACTION** (Eligibility: ~100%)

**Next Steps**:
1. **Order biomarker tests** (HER2 IHC, HRD if not done)
2. **Contact trial site** (within 48 hours)
3. **Pre-screen Ayesha** (get on coordinator's radar)
4. **Decision at Week 2**: Enroll if eligible
5. **Prepare medical records** (surgical report, pathology, CA-125 history)

**Expected Timeline**:
- Week 1: Complete L1 chemo (cycle 6)
- Week 2: Biomarker results available
- Week 3: Enroll in trial (if eligible) or proceed with SOC maintenance


---

## üéØ VALUE PROPOSITION

**WIN-WIN SCENARIO**:
- If eligible (100% chance) ‚Üí Access to experimental therapy
- If not eligible ‚Üí Gets proven SOC (PARP or bevacizumab maintenance)
- Either way, Ayesha receives appropriate care

**Risk-Benefit**: Low risk (pre-screening doesn't commit to enrollment), high reward (cutting-edge therapy)

---

## üìä PROVENANCE

**Generated By**: Zo (Lead Commander)  
**Pipeline Version**: v2.0 (Modular)  
**Data Source**: AstraDB vector search + Multi-stage filtering  
**Semantic Match Score**: 0.000  
**Composite Score**: 0.97 (Stage 1: 0.90, Stage 2: 0.95, Stage 3: 1.00, Stage 4: 1.00)  
**LLM Analysis**: Gemini gemini-2.5-pro  
**Quality**: ‚úÖ COMMANDER-GRADE INTELLIGENCE (Modular Pipeline v2.0)

---

**RESEARCH USE ONLY (RUO)** - This intelligence report is for research and strategic planning. All enrollment decisions must be reviewed by Ayesha's oncologist.

---

**‚öîÔ∏è FOR AYESHA!** ‚öîÔ∏è
